Prescription medication · Direct Oral Anticoagulant (Factor Xa Inhibitor)
edoxaban
Also sold as Savaysa. Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
Data updated 2026-05-15
- 5
- InteractionsFew interactions
- $13.95
- Brand price (NADAC)
edoxaban (Savaysa) is a prescription Direct Oral Anticoagulant (Factor Xa Inhibitor). Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
Savaysa is a medicine that helps to prevent blood clots. It is used to lower the chance of stroke in people with an irregular heartbeat (atrial fibrillation) and to treat blood clots in the legs or lungs.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$13.95/unit
Generic Available
No
DAIICHI SANKYO INC
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
Common side effects
Bleeding, Anemia (low red blood cells), Rash
Key warnings
Savaysa may not work as well to prevent strokes if you have atrial fibrillation and your kidneys are working very well (CrCl > 95 mL/min).
The sections below are summarized in plain English from edoxaban's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Savaysa is a factor Xa inhibitor. This means it blocks a substance in your blood called factor Xa. By blocking factor Xa, Savaysa helps to prevent blood from clotting.
Serious Warnings
Savaysa may not work as well to prevent strokes if you have atrial fibrillation and your kidneys are working very well (CrCl > 95 mL/min). If you stop taking Savaysa too soon, you have a higher risk of blood clots or stroke. If you get medicine injected into your spine while taking Savaysa, it could cause bleeding around your spine, which can lead to paralysis.
Known Drug Interactions
( 7.1 ) Rifampin: Avoid concomitant use ( 7.2 ) 7.1 Anticoagulants, Antiplatelets, Thrombolytics, and SSRIs/SNRIs Co-administration of anticoagulants, antiplatelet drugs, thrombolytics and SSRIs or SNRIs may increase the risk of bleeding. 7.2 P-gp Inducers Avoid the concomitant use of SAVAYSA with rifampin [see Clinical Pharmacology (12.3) ] .
Mechanism: Rifampin causes your body to clear the blood thinner too quickly, which could make the medicine fail to prevent blood clots.
7 DRUG INTERACTIONS Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding.
Mechanism: Taking these medicines together can increase your risk of serious bleeding.
Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with anticoagulants, aspirin, other platelet aggregation inhibitors, and/or NSAIDs [see Warnings and Precautions (5.3) ] . In clinical studies with SAVAYSA concomitant use of aspirin (low dose ≤ 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of Clinically Relevant Bleeding. Carefully monitor for bleeding in patients who require chronic treatment with low dose aspirin and/or NSAIDs [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] .
Mechanism: Both drugs affect how your blood clots, which can lead to more bleeding when used together.
Concomitant use of carbamazepine with rivaroxaban, apixaban, dabigatran, and edoxaban (direct acting oral anticoagulants) is expected to result in decreased plasma concentration of these anticoagulants that may be insufficient to achieve the intended therapeutic effect. In general, coadministration of carbamazepine with rivaroxaban, apixaban, dabigatran, and edoxaban should be avoided.
Mechanism: Carbamazepine speeds up how your body clears edoxaban, which can make the blood thinner less effective.
dabigatran etexilate edoxaban ↑ dabigatran ↑ edoxaban Refer to the dabigatran etexilate or edoxaban prescribing information for recommendations regarding co-administration. The specific recommendations are based on indication, renal function, and effect of the co-administered P-gp inhibitors on the concentration of dabigatran or edoxaban. Clinical monitoring is recommended when a DOAC not affected by CYP3A4 but transported by P-gp, including dabigatran etexilate and edoxaban, is co-administered with darunavir /ritonavir.
Mechanism: Darunavir stops a specific protein from moving edoxaban out of the body, which can increase the amount of medicine in your blood.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if I'm bleeding?
Can I take aspirin or other pain relievers with Savaysa?
Will Savaysa interact with other medications I am taking?
How often will I need blood tests while taking Savaysa?
What if I need to have a surgery or dental procedure?
Can I drink alcohol while taking Savaysa?
What if I have kidney problems?
What if I have liver problems?
Are there any foods I should avoid while taking Savaysa?
What are the common side effects of edoxaban?
Does edoxaban interact with other medications?
What drug class is edoxaban?
What pregnancy or breastfeeding source fields are listed for edoxaban?
Related Medications in Direct Oral Anticoagulant (Factor Xa Inhibitor)
Other drugs grouped near edoxaban - same-class peers and common alternatives.
apixaban
Eliquis
Apixaban (Eliquis) is a medicine that helps prevent blood clots.
Compare with edoxaban →
aspirin
Bayer, Ecotrin
Aspirin is a common medicine used to relieve minor pain.
Compare with edoxaban →
cilostazol
Pletal
Cilostazol is a medicine that helps improve walking distance in people with leg pain due to poor circulation.
Compare with edoxaban →
clopidogrel
Plavix
Clopidogrel is a drug that helps to prevent blood clots.
Compare with edoxaban →
dabigatran
Pradaxa
Dabigatran (Pradaxa) is a drug that helps to prevent blood clots from forming.
Compare with edoxaban →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on edoxaban
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for edoxaban
The FDA label for edoxaban (sold under brand names such as Savaysa) classifies it as a prescription-only medication in the Direct Oral Anticoagulant (Factor Xa Inhibitor) class. Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. Official labeling lists 4 commonly reported side effects, including Bleeding, Anemia (low red blood cells), Rash.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 5 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: July 10, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages